Tetanus Toxoid Vaccines Market

The tetanus toxoid vaccines market was valued at USD 4,587.4 Mn by 2019. Rising prevalence of Clostridium tetani infection in the developing regions primarily drives the tetanus toxoid vaccines market growth. Furthermore, recent advancements in the technology transfer process regarding the development of polyvalent vaccines provide a positive impetus to market growth.

Tetanus is an infectious disease which is caused by the bacterium Clostridium tetani, which affects the central nervous system resulting in lockjaw and muscle stiffness, difficulty in breathing, and eventually causes death if not treated early. As per the latest research citings provided by the World Health Organization (WHO), in 2017 approximately 38,000 people worldwide died due to the tetanus infection. The further in-depth analysis provides vital information regarding the clinical manifestation of tetanus infection which are headache, seizures, sweating, fever, muscle spams, etc.

The major segments related to the tetanus toxoid vaccines market are: 

By Type (2017–2027; US$ Mn)

Monovalent

Polyvalent

By End User (2017–2027; US$ Mn)

Hospitals

Specialty Clinics

Others

Geography Segment (2017–2027; US$ Mn)

North America

U.S.
Canada

Europe

United Kingdom
Germany
Russia
France
Italy
Spain
Ukraine
Rest of Europe

Asia Pacific

China
Japan
Rest of Asia Pacific

Latin America (LATAM)

Brazil
Mexico
Rest of Latin America

Middle East and Africa (MEA)

GCC
Rest of MEA 

Justification for study?

• The intention of the study is to give a comprehensive outlook of the global tetanus toxoid vaccines market
• The overall segmentation of the tetanus toxoid vaccines market, by type, end-user, and geography is minutely studied. Monovalent and hospitals are dominating the type and end-user segments respectively
• Growing incidence of Clostridium tetani infection worldwide
• Compulsory immunization programs adopted throughout the globe and the increasing popularity of polyvalent vaccines together accentuate the market growth

Report gist?

• The study of the global tetanus toxoid vaccines market includes qualitative analysis of factors such as drivers, restraints, and opportunities
• The report covers a qualitative and quantitative analysis of the overall market segmented on the basis of type and end-user and categorization of the same at geography level
• This research report presents the analysis of each segment from 2017 to 2027 in which 2019 is considered as the base year. The compounded annual growth rate is calculated for the respective segments from 2020 to 2027

The study includes the profiles of major market players with a significant global and regional presence along with top company positioning. 

Significant customers?

• This study is suitable for industry participants and stakeholders in the biopharmaceutical manufacturers actively engaged in the production and marketing of tetanus toxoid vaccines due to the  rising incidence of Clostridium tetani infection worldwide
• The report will benefit formulation scientist engaged in the technology transfer segment for the development of polyvalent vaccines
• Managers with financial institutions looking to publish recent and forecasted statistics pertaining to tetanus toxoid vaccines market
• Financial institutions, venture capitalist, analysts, investors, government organizations, policymakers, regulatory authorities, researchers, looking for insights into the market to determine future strategies 

Segment Analysis

Polyvalent vaccines are representing the largest market share in the types segment for the tetanus toxoid vaccines market. Frequent skin laceration by rusted utensils, tools, and repeated exposure to contaminated surfaces such as soil, animal and human feces, etc. causes the transmission of the Clostridium tetani bacteria in human beings. It is available in different combination such as diphtheria, tetanus, and pertussis (DTaP) and Diphtheria and Tetanus (DT) which are mentioned in the compulsory immunization program for newborn babies worldwide. Monovalent vaccines are going to showcase steady market growth during the forecast period as a growing incidence of clostridium tetani infection in the middle and low-income countries primarily drives the monovalent vaccines market growth. It is given to the adult population who have never received tetanus vaccines during their childhood and thus monovalent vaccine is given to developing a strong immune response.

Hospitals are currently leading the end-user segment for the tetanus toxoid vaccines market. Compulsory immunization of tetanus toxoid vaccines in children throughout the globe has resulted in a significant increase in the number of inpatient visits to the primary healthcare centers worldwide. The proactive initiative adopted by Government healthcare agencies to provide free vaccines to government-sponsored hospitals to encourage the immunization program to further consolidate market growth. Specialty clinics are expected to register rampant market growth in the near future owing to the increasing disposable income in middle-income families, which frequently visit specialty clinics for immunization of children at affordable prices.

North America is presently dominating the geography segment for the tetanus toxoid vaccines market. Mandatory immunization of children as per the vaccination guidelines provided by the USFDA primarily drives the tetanus toxoid vaccines market growth. Existence of well-established healthcare infrastructure and affordable reimbursement scenarios associated with immunization programs further accentuate the market growth in the region. Europe is placed in the second position in the regional segment owing to the domicile of major players such as Merck & Co. Inc., Sanofi Pasteur, GlaxoSmithKline, Plc. etc determine the market growth in the region. The Asia Pacific is anticipated to be the fastest-growing regional segment for the tetanus toxoid vaccines market. The rising incidence of Clostridium tetani infection determines the market growth in the region. The emergence of local players and developing healthcare infrastructure further bolster the market growth in the Asia Pacific region.